Tactile Systems Technology earnings release, August 10, 2026

Tactile Systems Technology Inc (TCMD) · Form 8-K, Item 2.02 · Filed · SEC filing

Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results

MINNEAPOLIS, MN, August 10th, 2026 – Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Summary and Recent Business Highlights:

​

“We are encouraged by our strong momentum in the second quarter. We delivered solid revenue growth, expanded gross margin, and generated meaningful adjusted EBITDA, underscoring the strength of our business model and our team’s disciplined execution,” said Sheri Dodd, Chief Executive Officer of Tactile Medical. “Our core lymphedema business remains healthy and our view of the long-term opportunity for AffloVest to be a leading high frequency chest wall oscillation technology therapy is unchanged despite the impact of a temporary inventory management dynamic related to the launch of our next-generation AffloVest system during the quarter.”

​

Ms. Dodd continued, “Operationally, we made tangible progress furthering our broader strategy. We advanced integration activities for LymphaTech, which expands our portfolio across the lymphedema care continuum, launched our next-generation AffloVest system, and secured exclusive Department of Veterans Affairs and Department of Defense distribution rights for MyoSleeve. These product and capability investments strengthen and broaden our patient reach and market expansion, enabling diagnostic and therapy options for patients and providers. With a clear growth and leverage strategy and a differentiated portfolio, we believe Tactile Medical is well-positioned for sustainable, profitable growth in the years ahead.”

​

Second Quarter 2026 Financial Results

Total revenue in the second quarter of 2026 increased $6.8 million, or 9%, to $85.7 million, compared to $78.9 million in the second quarter of 2025. The increase in total revenue was attributable to an increase of $7.7 million, or 12%, in sales and rentals of the lymphedema product line, partially offset by a decrease of $0.9 million, or 7%, in sales of the airway clearance product line, due to temporary inventory management dynamics associated with the launch of the Company’s next-generation AffloVest system among a few large DME providers during the quarter.

Gross profit in the second quarter of 2026 increased $6.6 million, or 11%, to $65.3 million, compared to $58.8 million in the second quarter of 2025. Gross margin was 76% of revenue, compared to 75% of revenue in the second quarter of 2025. Gross margin improvement reflected continued operating execution and product cost discipline.

Operating expenses in the second quarter of 2026 increased $3.8 million, or 7%, to $58.5 million, compared to $54.7 million in the second quarter of 2025.

The increase primarily reflected continued investments to support long-term growth initiatives.

Operating income was $6.8 million in the second quarter of 2026, compared to $4.1 million in the second quarter of 2025.

Income tax benefit was $0.4 million in the second quarter of 2026, compared to an income tax expense of $1.3 million in the second quarter of 2025.

Net income in the second quarter of 2026 was $7.8 million, or $0.34 per diluted share, compared to $3.2 million, or $0.14 per diluted share, in the second quarter of 2025.

Weighted average shares used to compute diluted net income per share were 23.1 million and 23.2 million for the second quarters of 2026 and 2025, respectively.

Adjusted EBITDA was $11.4 million in the second quarter of 2026, compared to $7.7 million in the second quarter of 2025, reflecting revenue growth, gross margin expansion and disciplined expense management.

First Six Months 2026 Financial Results

Total revenue for the six months ended June 30, 2026, increased $20.8 million, or 15%, to $161.0 million, compared to $140.2 million for the six months ended June 30, 2025. The increase in total revenue was attributable to an increase of $19.3 million, or 17%, in sales and rentals of the lymphedema product line and an increase of $1.5 million, or 6%, in sales of the airway clearance product line for the six months ended June 30, 2026, compared to the six months ended June 30, 2025.

Net income for the six months ended June 30, 2026, was $6.0 million, or $0.26 per diluted share, compared to $0.2 million, or $0.01 per diluted share, for the six months ended June 30, 2025.

Weighted average shares used to compute diluted net income per share were 23.1 million and 23.7 million for the six months ended June 30, 2026 and 2025, respectively.

Adjusted EBITDA was $15.1 million in the six months ended June 30, 2026, compared to $7.4 million in the six months ended June 30, 2025.

Balance Sheet Summary

As of June 30, 2026, the Company had $69.9 million in cash and no outstanding borrowings under its credit agreement, compared to $83.4 million in cash and no outstanding borrowings under its credit agreement as of December 31, 2025.

The Company repurchased $5.3 million of its stock during the second quarter under its repurchase program. As of June 30, 2026, $18.7 million remained available under the Company’s $25.0 million share repurchase program, which expires November 3, 2027.

2026 Financial Outlook

The Company is updating its 2026 financial outlook and now expects full year 2026 total revenue in the range of $360 million to $366 million, representing growth of approximately 9% to 11% year-over-year, compared to total revenue of $329.5 million in 2025. The Company’s prior 2026 guidance expectation was total revenue in the range of $360 million to $368 million, representing growth of approximately 9% to 12% year-over-year.

The Company continues to expect full year 2026 adjusted EBITDA in the range of $49 million to $51 million, compared to adjusted EBITDA of $44.8 million in 2025.... (truncated)cts continued confidence in the Company's lymphedema product line, partially offset by a more conservative view of airway clearance product line ordering patterns as certain DME providers work through near-term elevated inventory levels related to the launch of the Company’s next-generation AffloVest system.

Conference Call

Management will host a conference call with a question-and-answer session at 5:00 p.m. Eastern Time on August 10, 2026, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13761142. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13761142. The webcast will be archived at investors.tactilemedical.com.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic respiratory conditions by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Financial statements

Income Statement

Tactile Systems Technology, Inc. — investorrelations@tactilemedical.com

Tactile Systems Technology, Inc. – Condensed Consolidated Statements of Operations – (Unaudited) – Three Months Ended – June 30, – 2026Tactile Systems Technology, Inc. – Condensed Consolidated Statements of Operations – (Unaudited) – Three Months Ended – June 30, – 2025Tactile Systems Technology, Inc. – Condensed Consolidated Statements of Operations – (Unaudited) – Six Months Ended – June 30, – 2026Tactile Systems Technology, Inc. – Condensed Consolidated Statements of Operations – (Unaudited) – Six Months Ended – June 30, – 2025
RevenueSales revenue76,48970,531143,455123,000
RevenueRental revenue9,2098,37417,51017,173
RevenueTotal revenue85,69878,905160,965140,173
Cost of revenueCost of sales revenue17,62817,48332,88731,374
Cost of revenueCost of rental revenue2,7212,6295,1154,660
Cost of revenueTotal cost of revenue20,34920,11238,00236,034
Gross profitGross profit - sales revenue58,86153,048110,56891,626
Gross profitGross profit - rental revenue6,4885,74512,39512,513
Gross profit65,34958,793122,963104,139
Operating expensesSales and marketing32,01230,03964,74457,555
Operating expensesResearch and development2,5012,0185,2773,759
Operating expensesReimbursement, general and administrative23,36022,03446,40442,032
Operating expensesIntangible asset amortization and earn-out6506191,2461,252
Operating expensesTotal operating expenses58,52354,710117,671104,598
Operating expensesIncome (loss) from operations6,8264,0835,292-459
Operating expensesInterest income5618501,2271,745
Operating expensesInterest expense-19-410-47-834
Operating expensesOther income11
Operating expensesIncome before income taxes7,3684,5246,472453
Operating expensesIncome tax (benefit) expense-4171,307450210
Operating expensesNet income7,7853,2176,022243
Net income per common shareBasic0.340.140.270.01
Net income per common shareDiluted0.340.140.260.01
Weighted-average common shares used to compute net income per common shareBasic22,676,67323,092,46922,620,54623,399,848
Weighted-average common shares used to compute net income per common shareDiluted23,058,90223,237,67123,135,04023,679,220

Income Statement

Three Months Ended — The following table summarizes revenue by product line for the three and six months ended June 30, 2026 and 2025: (in thousands)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
RevenueLymphedema products73,63065,969135,851116,524
RevenueAirway clearance products12,06812,93625,11423,649
RevenueTotal85,69878,905160,965140,173
Percentage of total revenueLymphedema products86.0%84.0%84.0%83.0%
Percentage of total revenueAirway clearance products14.0%16.0%16.0%17.0%
Percentage of total revenueTotal100.0%100.0%100.0%100.0%

Income Statement

Tactile Systems Technology, Inc. — The following table contains a reconciliation of net income to Adjusted EBITDA for the year ended December 31, 2025:

Tactile Systems Technology, Inc. – Reconciliation of Net Income to Non-GAAP Adjusted EBITDA – (Unaudited) – Year Ended – December 31, 2025
Net income19,086
Interest (income) expense, net-2,059
Income tax expense12,253
Depreciation and amortization6,644
Stock-based compensation8,357
Executive transition costs491
Adjusted EBITDA44,772

Income Statement

Tactile Systems Technology, Inc.

Reconciliation of FY 2026 GAAP Net Income to Adjusted EBITDA Guidance – Tactile Systems Technology, Inc. – (Unaudited) – Year Ended – December 31, 2026 – LowReconciliation of FY 2026 GAAP Net Income to Adjusted EBITDA Guidance – Tactile Systems Technology, Inc. – (Unaudited) – Year Ended – December 31, 2026 – High
Net income23,23024,670
Interest (income) expense, net-2,380-2,380
Income tax expense9,4209,980
Depreciation and amortization7,5107,510
Stock-based compensation8,5508,550
Acquisition & integration costs1,3101,310
Executive transition costs360360
Litigation-related costs1,0001,000
Adjusted EBITDA49,00051,000

Balance Sheet

Tactile Systems Technology, Inc. — investorrelations@tactilemedical.com

Tactile Systems Technology, Inc. – Condensed Consolidated Balance Sheets – (Unaudited) – June 30, – 2026Tactile Systems Technology, Inc. – Condensed Consolidated Balance Sheets – (Unaudited) – December 31, – 2025
Current assetsCash69,85383,446
Current assetsAccounts receivable, net43,14043,876
Current assetsNet investment in leases14,92715,754
Current assetsInventories16,84514,025
Current assetsIncome taxes receivable912
Current assetsPrepaid expenses and other current assets11,9258,066
Current assetsTotal current assets157,602165,167
Non-current assetsProperty and equipment, net5,8495,117
Non-current assetsRight of use operating lease assets12,55313,798
Non-current assetsIntangible assets, net44,74739,167
Non-current assetsGoodwill39,55431,063
Non-current assetsDeferred income taxes8,7039,783
Non-current assetsOther non-current assets10,6609,847
Non-current assetsTotal non-current assets122,066108,775
Non-current assetsTotal assets279,668273,942
Current liabilitiesAccounts payable7,9234,968
Current liabilitiesAccrued payroll and related taxes15,61519,378

Cash Flow

Tactile Systems Technology, Inc. — investorrelations@tactilemedical.com

Tactile Systems Technology, Inc. – Condensed Consolidated Statements of Cash Flows – (Unaudited) – Six Months Ended June 30, – 2026Tactile Systems Technology, Inc. – Condensed Consolidated Statements of Cash Flows – (Unaudited) – Six Months Ended June 30, – 2025
Cash flows from operating activitiesNet income6,022243
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization3,4503,385
Adjustments to reconcile net income to net cash provided by operating activities:Deferred income taxes42-22
Adjustments to reconcile net income to net cash provided by operating activities:Stock-based compensation expense4,0404,005
Adjustments to reconcile net income to net cash provided by operating activities:Loss on disposal of property and equipment and intangibles7368
Changes in assets and liabilities, net of acquisition:Accounts receivable, net75511,851
Changes in assets and liabilities, net of acquisition:Net investment in leases82783
Changes in assets and liabilities, net of acquisition:Inventories-2,8201,555
Changes in assets and liabilities, net of acquisition:Income taxes payable-2,245-611
Changes in assets and liabilities, net of acquisition:Prepaid expenses and other assets-5,174-4,735
Changes in assets and liabilities, net of acquisition:Right of use operating lease assets-351-289
Changes in assets and liabilities, net of acquisition:Accounts payable2,8862,319
Changes in assets and liabilities, net of acquisition:Accrued payroll and related taxes-3,763-5,245
Changes in assets and liabilities, net of acquisition:Accrued expenses and other liabilities-8272,567
Changes in assets and liabilities, net of acquisition:Net cash provided by operating activities2,91515,174
Cash flows from investing activitiesPayments related to acquisition, net of cash acquired-6,226
Cash flows from investing activitiesPurchases of property and equipment-2,102-748
Cash flows from investing activitiesIntangible assets expenditures-52-56
Cash flows from investing activitiesPayment for exclusive distribution agreement-3,000
Cash flows from investing activitiesNet cash used in investing activities-11,380-804
Cash flows from financing activitiesPayments on note payable-1,500
Cash flows from financing activitiesProceeds from exercise of common stock options19710
Cash flows from financing activitiesProceeds from the issuance of common stock from the employee stock purchase plan1,032843
Cash flows from financing activitiesPayments for repurchases of common stock-6,357-26,562
Cash flows from financing activitiesNet cash used in financing activities-5,128-27,209
Cash flows from financing activitiesNet decrease in cash-13,593-12,839
Cash flows from financing activitiesCash – beginning of period83,44694,367
Cash flows from financing activitiesCash – end of period69,85381,528
Supplemental cash flow disclosureCash paid for interest34828
Supplemental cash flow disclosureCash paid for taxes2,645892
Supplemental cash flow disclosureAccrued excise tax on stock repurchases$—210
Supplemental cash flow disclosureCapital expenditures incurred but not yet paid14758
Full release

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements, including guidance for the full year 2026. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the Company’s ability to obtain reimbursement from third-party payers for its products; adverse economic conditions, including inflation, rising interest rates or a recession; the adequacy of the Company’s liquidity to pursue its business objectives; price increases for supplies and components; wage and component price inflation; loss of a key supplier or other supply chain disruptions; entry of new competitors and/or competitive products; compliance with and changes in federal, state and local government laws and regulations; technological obsolescence of, or quality issues with, the Company’s products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

This press release includes the non-GAAP financial measure of Adjusted EBITDA, which differs from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). Adjusted EBITDA in this release represents net income, plus interest expense, net, or less interest income, net, less income tax benefit or plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense, plus litigation-related costs, plus executive transition costs, and plus acquisition and integration costs. Reconciliation of this non-GAAP financial measure to its most directly comparable GAAP measure is included in this press release.

This non-GAAP financial measure is presented because the Company believes it is a useful indicator of its operating performance. Management uses this measure principally as a measure of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating plan and financial projections. The Company believes this measure is useful to investors as supplemental information and because it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company also believes this non-GAAP financial measure is useful to its management and investors as a measure of comparative operating performance from period to period. In addition, Adjusted EBITDA is used as a performance metric in the Company’s compensation program.... (truncated) future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating non-GAAP financial measures, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP financial measures should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using non-GAAP financial measures on a supplemental basis. The Company’s definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.

Investor Inquiries:

Sam Bentzinger

Gilmartin Group investorrelations@tactilemedical.com

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

The following table summarizes revenue by product line for the three and six months ended June 30, 2026 and 2025:

​

The following table contains a reconciliation of net income to Adjusted EBITDA for the three and six months ended June 30, 2026 and 2025, as well as the dollar and percentage change between the comparable periods:

“N.M.” Not Meaningful

​

The following table contains a reconciliation of net income to Adjusted EBITDA for the year ended December 31, 2025:

​

​

The following table contains a reconciliation of GAAP net income guidance range to the Adjusted EBITDA guidance range for the twelve months ending December 31, 2026:

​

Investor Inquiries:

Sam Bentzinger

Gilmartin Group investorrelations@tactilemedical.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Tactile Systems Technology earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.